Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.

Gene Set Enrichment Analysis (GSEA) of RNA-seq data from eight PDXs treated with DTN and six with DTV showed highly significant downregulation (FDR < 0.0001) of the same cell cycle regulatory networks by these treatments in the sensitive versus resistant PDXs (Fig.

also in 132,142 other papers